Navigation Links
GeneTex Antibody Company to Launch a Line of New Zebrafish Primary Antibodies
Date:6/28/2011

IRVINE, Calif., June 28, 2011 /PRNewswire/ -- GeneTex, a leading manufacturer of high quality antibodies, is pleased to announce that they will be launching a full line of zebrafish antibodies.

Zebrafish have been increasingly utilized as a model organism for scientific research. Due to their short lifecycles and relatively large clutch sizes, they are a useful model for genetic studies. Zebrafish eggs are externally fertilized; therefore, researchers can control and manipulate the embryos from the moment of fertilization. In addition, their embryos are transparent, so researchers are able to observe the changes that occur throughout the developmental stages of the embryo.

"We believe the zebrafish is an excellent model organism for biological research," said Dr. Kristina Beiswenger, Product Specialist at GeneTex, "however, this field has long been overlooked and lacks quality antibody reagents. GeneTex is fully committed to developing high quality antibodies specifically validated with zebrafish samples. We will continue to expand this product line to satisfy the needs of zebrafish research."

Many zebrafish tissues and organ systems, including the kidney, pancreas, bones and heart, are comparable to those of higher mammals and humans. The relatively large size, large number and external development of zebrafish embryos make them especially agreeable to manipulation by a variety of chemical, physical and genetic methods.

GeneTex is launching one of the largest collections of zebrafish antibodies that are validated for western blotting, immunofluorescence (ICC/IF), immunohistochemistry (IHC) and other applications. Almost all of the antibodies in the line are antigen-affinity purified, which results in higher quality antibodies.

For additional information on GeneTex's full line of zebrafish antibodies, call toll-free 877-GENETEX (436-3839) or visit www.GeneTex.com/zebrafish.

About GeneTex:

GeneTex is an antibody company that was founded by scientists in 1997. They strive to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation.  GeneTex has over 35,000 primary antibodies in its catalog that are all backed by a 100% Satisfaction Guarantee.  


'/>"/>
SOURCE GeneTex
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
4. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
5. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
6. SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification.
7. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
8. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
9. PacificGMP and Actinium Pharmaceuticals Announce Agreements for cGMP Antibody Manufacturing and Stability Testing
10. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
11. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):